Biotechnology
Medical
Pharmaceutical
Rigel Pharmaceuticals
$2.139876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.12 (5.94%) Today
-$0.01 (-0.47%) After Hours
Why Robinhood?
You can buy or sell RIGL and other stocks, options, ETFs, and crypto commission-free!
About
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. Read More The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Employees
158
Headquarters
South San Francisco, California
Founded
1996
Market Cap
357.76M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.24M
High Today
$2.26
Low Today
$2.07
Open Price
$2.11
Volume
720.33K
52 Week High
$3.94
52 Week Low
$1.96
Collections
Biotechnology
Medical
Pharmaceutical
Therapy
Health
Technology
News
Seeking AlphaMay 16
Rigel begins patient enrollment in late-stage AHIA study
Rigel Pharmaceuticals (NASDAQ:RIGL) has enrolled first patient in a Phase 3 trial of fostamatinib disodium hexahydrate in warm antibody autoimmune hemolytic anemia (AIHA). The trial protocol calls for ~80 patients in a 24-week study with topline results projected for early 2021. The primary endpoint will be a durable hemoglobin response by week 24, defined as Hgb > 10 g/dL and > 2 g/dL greater than baseline. Currently, fostamatinib is commercially available in U.S. under the brand name TAVALISSE. Rigel ...
Seeking AlphaMay 10
Rigel Reports An Earnings Beat, But The Market Shrugs It Off
Despite the positive updates, the share price remains in the lower $2.00 range. However, the charts show a systematic chart movement that is leading to a potential breakout. TAVALISSE appears to be gaining traction in the ITP market as physicians begin to move it up into earlier lines of therapy and above the competition. Rigel recently reported their Q1 earnings with a beat on EPS and revenue. Despite the good news, the market was unconcerned as the overall market is focused on trade talks. Rigel Pharma...
Price Paid on Robinhood
17% Lower
Right Now
52 Week Low
$1.96
Average Price Paid
$2.57
52 Week High
$3.94
Earnings
-$0.18
-$0.11
-$0.04
$0.03
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, After Hours